ETFs Celltrion, Inc.

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. 2026-08-28			5-day change	1st Jan Change
190,700.00 ^KRW	-0.31%		-0.83%	+10.63%

08-25	Celltrion Launches Omlyclo 300 Mg Strength In Key European Markets	CI
08-23	Celltrion Submits Marketing Application for Keytruda Biosimilar in South Korea	MT

ETFs positioned on Celltrion, Inc.

Name	YTD change	Weight	AuM
STATE STREET SPDR MSCI EMERGING MARKETS FOSSIL FUEL RESERVES FREE ETF - USD	+24.34%	-.--%	182 M€
CI GROWTH ASSET ALLOCATION ETF -CAD	0.00%	-.--%	67 M€
COLUMBIA EM EX-CHINA ETF - USD	+33.24%	-.--%	2,017 M€
STATE STREET SPDR MSCI EM ASIA UCITS ETF - USD	+28.03%	-.--%	1,587 M€
VANGUARD FTSE ALL-WORLD UCITS ETF - USD	+13.79%	-.--%	27,154 M€
ISHARES MSCI KOREA UCITS ETF USD (ACC) - USD	-.--%	2.91%	825 M€
HSBC MSCI KOREA CAPPED UCITS ETF - USD	+85.24%	2.28%	420 M€
ISHARES HEALTHCARE INNOVATION UCITS ETF - USD	+18.00%	2.01%	1,260 M€
GLOBAL X AGING POPULATION ETF - USD	+6.54%	1.94%	94 M€
ISHARES MSCI SOUTH KOREA ETF - USD	+85.35%	1.6%	27,337 M€
ISHARES MSCI KOREA UCITS ETF USD (DIST) - USD	+86.40%	1.53%	1,139 M€
FRANKLIN FTSE SOUTH KOREA ETF - USD	+85.65%	1.42%	1,505 M€
ISHARES MSCI SOUTH KOREA ETF - AUD	+64.49%	1.37%	180 M€
XTRACKERS MSCI KOREA UCITS ETF 1C - USD	+87.60%	1.31%	595 M€
WISDOMTREE EMERGING MARKETS QUALITY DIVIDEND GROWTH FUND - USD	+29.28%	1.24%	148 M€
AMUNDI MSCI EMERGING EX CHINA ESG SELECTION - UCITS ETF DR (C) - USD	+22.17%	0.65%	1,000 M€
HSBC MSCI EMERGING MARKETS ISLAMIC SCREENED CAPPED UCITS ETF (ACC) - USD	+64.15%	0.62%	173 M€
ISHARES MSCI EM ISLAMIC UCITS ETF - USD	+49.37%	0.61%	794 M€
VANGUARD FTSE DEVELOPED ASIA PACIFIC EX JAPAN UCITS ETF ACCUMULATING - USD	+43.47%	0.57%	1,037 M€
FIRST TRUST BLOOMBERG EMERGING MARKET DEMOCRACIES ETF - USD	+34.08%	0.53%	39 M€
ISHARES ASIA 50 ETF - USD	+42.12%	0.51%	5,038 M€
ISHARES MSCI EM CONSUMER GROWTH UCITS ETF - USD	-2.69%	0.51%	44 M€
FIRST TRUST EMERGING MARKETS HUMAN FLOURISHING ETF - USD	+43.93%	0.51%	122 M€
VANGUARD FTSE DEVELOPED ASIA PACIFIC EX JAPAN UCITS ETF - USD	+40.97%	0.5%	2,019 M€
ISHARES ASIA 50 ETF - AUD	+31.23%	0.47%	1,182 M€
ISHARES ESG ADVANCED MSCI EM ETF - USD	+23.47%	0.47%	164 M€
AMUNDI MSCI AC FAR EAST EX JAPAN ESG SELECTION - UCITS ETF - USD	+16.85%	0.45%	5 M€
ISHARES MSCI ASIA EX JAPAN CLIMATE ACTION ETF - USD	+9.73%	0.45%	865 M€
FREEDOM 100 EMERGING MARKETS ETF - USD	+33.88%	0.44%	3,377 M€
BMO LOW VOLATILITY EMERGING MARKETS EQUITY ETF - DISTRIBUTING - CAD	+29.39%	0.43%	68 M€
UBS MSCI EM EX CHINA UCITS ETF (USD) A-ACC - USD	+36.44%	0.41%	100 M€
ISHARES MSCI EM EX-CHINA UCITS ETF - USD	+35.75%	0.39%	5,563 M€
HSBC MSCI AC FAR EAST EX JAPAN UCITS ETF - USD	+32.14%	0.37%	457 M€
STRIVE EMERGING MARKETS EX-CHINA ETF - USD	+38.87%	0.35%	141 M€
UBS MSCI EM CLIMATE PARIS ALIGNED UCITS ETF ACC - USD	+21.61%	0.34%	706 M€
STATE STREET SPDR MSCI EMERGING MARKETS UCITS ETF - USD	+24.84%	0.34%	2,215 M€

1 2 3 4 5

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,956

Sector

Biotechnology & Medical Research

More about the company